许多患有乳腺癌（BC）的青少年和年轻成人（AYA）患者接受辅助治疗作为初始治疗，长期骨髓抑制是潜在的并发症，但没有研究评估种族/民族对骨骼发育的影响AYA BC 幸存者的骨髓抑制。从加州癌症登记处确定了年龄 15-39 岁诊断为 BC（2006-2018 年）且存活 ≥ 2 年的女性患者，并与全州住院数据相关联。我们估计了出院诊断后 ≥ 2 年期间出现的骨髓抑制迟发效应（如白细胞减少、贫血、血小板减少、出血和感染/败血症）的累积发生率。我们使用多变量 Cox 比例风险回归研究了社会人口统计学和临床​​因素对后期效应的影响。在 11,293 名患者中，42.8% 为非西班牙裔 (nH) 白人，28.8% 为西班牙裔，19.5% 为亚裔/太平洋岛民，7.5% 为 nH黑色的。在多变量分析中，新罕布什尔州黑人（与新罕布什尔州白人相比）贫血风险最高[风险比 (HR) 1.72，95% 置信区间 (CI) 1.47-2.02]、白细胞减少症（HR 1.56，CI 1.14-2.13）、血小板减少症（ HR 1.46，CI 1.08-1.99）、严重感染/败血症（HR 1.64，CI 1.4-1.92）和出血（HR 1.89，CI 1.39-2.58）。西班牙裔患贫血（HR 1.17，CI 1.04-1.32）、出血（HR 1.4，CI 1.12-1.76）和严重感染/败血症（HR 1.36，CI 1.21-1.52）的风险较高。亚洲/太平洋岛民发生出血的风险较高（HR 1.33，CI 1.03-1.72）。来自社区社会经济地位较低的患者感染/败血症的风险高出 20%（HR 1.21，CI 1.1-1.34），但与其他后期影响没有关联。我们发现，新罕布什尔州黑人、西班牙裔和亚裔的 AYA与新罕布什尔州白人患者相比，太平洋岛民种族/族裔在辅助治疗后出现多种迟发效应的风险更高。根据这些数据，提供者可以对这些高危幸存者进行血液学晚期效应的早期/频繁筛查。© 2024。外科肿瘤学会。

Many adolescent and young adult (AYA) patients with breast cancer (BC) receive adjuvant therapy as initial treatment, with long-term bone marrow suppression as a potential complication, but no studies have evaluated the impact of race/ethnicity on the development of bone marrow suppression in AYA BC survivors.Female patients ages 15-39 years diagnosed with BC (2006-2018) and surviving ≥ 2 years were identified from the California Cancer Registry and linked to statewide hospitalization data. We estimated the cumulative incidence of developing late effects of bone marrow suppression, such as leukopenia, anemia, thrombocytopenia, bleeding, and infection/sepsis, during hospital discharge diagnoses present ≥ 2 years after diagnosis. We examined the impact of sociodemographic and clinical factors on late effects using multivariate Cox proportional hazards regression.Of 11,293 patients, 42.8% were non-Hispanic (nH) White, 28.8% Hispanic, 19.5% nH Asian/Pacific Islander, and 7.5% nH Black. In multivariable analyses, nH Blacks had the highest risk (versus nH Whites) of anemia [hazard ratio (HR) 1.72, 95% confidence interval (CI) 1.47-2.02], leukopenia (HR 1.56, CI 1.14-2.13), thrombocytopenia (HR 1.46, CI 1.08-1.99), major infection/sepsis (HR 1.64, CI 1.4-1.92), and bleeding (HR 1.89, CI 1.39-2.58). Hispanics had a higher risk of developing anemia (HR 1.17, CI 1.04-1.32), bleeding (HR 1.4, CI 1.12-1.76), and major infections/sepsis (HR 1.36, CI 1.21-1.52). Asian/Pacific Islanders had only a higher risk of developing bleeding (HR 1.33, CI 1.03-1.72). Patients from a low neighborhood socioeconomic status had a 20% higher risk of infection/sepsis (HR 1.21, CI 1.1-1.34), but there were no associations for the other late effects.We identified that AYAs of nH Black, Hispanic, and Asian/Pacific Islander race/ethnicity are at an increased risk of several late effects after adjuvant therapy compared with nH White patients. From these data, providers can implement early/frequent screening of hematologic late effects in these high-risk survivors.© 2024. Society of Surgical Oncology.